Beta Bionics, Inc. (BBNX) Price & Analysis

Compare

53 Followers

BBNX Stock Chart & Stats

$13.94

Market closed

$13.94

Day’s Range― - ―

52-Week Range$8.89 - $32.71

Previous CloseN/A

VolumeN/A

Average Volume (3M)917.05K

Market Cap

$613.70M

Enterprise Value$582.91M

Total Cash (Recent Filing)$228.69M

Total Debt (Recent Filing)$7.69M

Price to Earnings (P/E)―

Beta1.18

Next Earnings

Feb 17, 2026

EPS Estimate

-0.4

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.33

Shares Outstanding44,024,630

10 Day Avg. Volume410,323

30 Day Avg. Volume917,055

Financial Highlights & Ratios

PEG Ratio-0.79

Price to Book (P/B)1.98

Price to Sales (P/S)2.31

P/FCF Ratio-2.91

Enterprise Value/Market Cap0.95

Enterprise Value/Revenue6.58

Enterprise Value/Gross Profit12.07

Enterprise Value/Ebitda-8.92

Forecast

1Y Price Target

$27.11

Price Target Upside94.48% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering9

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Adaptive Algorithm AdvantageAn adaptive learning algorithm that reduces required patient interaction can attract less-experienced prescribers and broaden the potential user base, supporting adoption beyond highly specialized centers.

Device DifferentiationDifferentiated device design and an easy user experience position the iLet system to capture share from incumbent insulin pumps by appealing to patients and prescribers seeking simplified automated insulin delivery.

Pipeline ExpansionDevelopment of a next-generation patch pump and a bihormonal option expands the addressable market and could accelerate new patient starts if regulatory clearances are obtained.

Bears Say

Financial Transparency And ProfitabilityPlans to stop disclosing specific new patient start figures combined with an ongoing lack of profitability reduce investor transparency and make it harder to support an elevated valuation.

Market Adoption UncertaintySmall-sample clinician surveys and softer-than-expected new patient starts indicate uncertain prescription uptake, which could limit the company’s ability to grow market share against larger competitors.

Regulatory ScrutinyAn FDA warning letter citing deficiencies in safety-reporting processes increases regulatory scrutiny and could force resource-intensive corrective actions that disrupt operations.

Beta Bionics, Inc. News

Oracle gets upgrade and downgrade: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

7d ago

MDT

WLK

Beta Bionics initiated with a Buy at UBS

UBS initiated coverage of Beta Bionics (BBNX) with a Buy rating and $24 price target Beta Bionics’ differentiated...

7d ago

BBNX

Beta Bionics initiated with a Buy at UBS

UBS initiated coverage of Beta Bionics (BBNX) with a Buy rating and $24 price target Published first on...

8d ago

BBNX

Beta Bionics price target lowered to $25 from $31 at Stifel

Stifel lowered the firm’s price target on Beta Bionics (BBNX) to $25 from $31 and keeps a Buy...

12d ago

BBNX

Beta Bionics discloses FDA warning letter

In a regulatory 8-K filing on Friday, the company stated: “On January 29, 2026, Beta Bionics (BBNX) received...

14d ago

BBNX

Beta Bionics price target lowered to $25 from $37 at Truist

Truist lowered the firm’s price target on Beta Bionics (BBNX) to $25 from $37 but keeps a Buy...

14d ago

BBNX

Beta Bionics initiated with a Hold at TD Cowen

TD Cowen initiated coverage of Beta Bionics (BBNX) with a Hold rating and $17 price target The company’s...

21d ago

BBNX

Is BBNX a Buy, Before Earnings?

Beta Bionics, Inc. (BBNX) is scheduled to report 4th quarter earnings on 02/17/2026, after the market closes. Regarding...

2d ago

BBNX

Balanced Risk-Reward Amid FDA Warning Letter Keeps Beta Bionics at Hold

TD Cowen analyst Mathew Blackman has maintained their neutral stance on BBNX stock, giving a Hold rating on...

14d ago

BBNX

Beta Bionics Receives FDA Warning Letter, Begins Remediation

Beta Bionics, Inc. ( ($BBNX) ) has shared an announcement. On January 29, 2026, Beta Bionics, Inc. disclosed...

17d ago

BBNX

Balancing Growth Potential and Emerging Uncertainty: TD Cowen Maintains Hold on Beta Bionics with $17 Price Target

Beta Bionics, Inc. (BBNX) has received a new Hold rating, initiated by TD Cowen analyst, . TD Cowen...

21d ago

BBNX

Beta Bionics price target lowered to $25 from $33 at Goldman Sachs

Goldman Sachs analyst David Roman lowered the firm’s price target on Beta Bionics (BBNX) to $25 from $33...

1M ago

BBNX

Midday Fly By: Job growth comes in below forecasts in December

The major averages were broadly higher near noon after the December nonfarm payrolls report. Stocks have shown resilience...

1M ago

Beta Bionics price target raised to $40 from $35 at Lake Street

Lake Street raised the firm’s price target on Beta Bionics (BBNX) to $40 from $35 and keeps a...

1M ago

BBNX

BBNX FAQ

What was Beta Bionics, Inc.’s price range in the past 12 months?

Beta Bionics, Inc. lowest stock price was $8.89 and its highest was $32.71 in the past 12 months.

What is Beta Bionics, Inc.’s market cap?

Beta Bionics, Inc.’s market cap is $613.70M.

When is Beta Bionics, Inc.’s upcoming earnings report date?

Beta Bionics, Inc.’s upcoming earnings report date is Feb 17, 2026 which is tomorrow.

How were Beta Bionics, Inc.’s earnings last quarter?

Beta Bionics, Inc. released its earnings results on Oct 28, 2025. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.423 by $0.093.

Is Beta Bionics, Inc. overvalued?

According to Wall Street analysts Beta Bionics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Beta Bionics, Inc. pay dividends?

Beta Bionics, Inc. does not currently pay dividends.

What is Beta Bionics, Inc.’s EPS estimate?

Beta Bionics, Inc.’s EPS estimate is -0.4.

How many shares outstanding does Beta Bionics, Inc. have?

Beta Bionics, Inc. has 44,024,630 shares outstanding.

What happened to Beta Bionics, Inc.’s price movement after its last earnings report?

Beta Bionics, Inc. reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.423. Following the earnings report the stock price went up 10.338%.

Which hedge fund is a major shareholder of Beta Bionics, Inc.?

Currently, no hedge funds are holding shares in BBNX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Beta Bionics, Inc. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-47.52%

Trailing 12-Months

Asset Growth

35.99%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Beta Bionics, Inc.

Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is based in Irvine, California.

Beta Bionics, Inc. (BBNX) Earnings & Revenues

Historic Earnings Reports

BBNX Company Deck

BBNX Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call presented several positive developments, including strong revenue growth, an increase in new patient starts, and an expanded presence in the pharmacy channel. However, there were concerns about increased operating expenses, a notable churn rate, and potential uncertainties from CMS proposals. Overall, the positive aspects outweigh the negative, reflecting a strong quarter and optimistic future guidance.View all BBNX earnings summaries

BBNX Stock 12 Month Forecast

Average Price Target

$27.11

▲(94.48% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","41":"$41","17.75":"$17.75","25.5":"$25.5","33.25":"$33.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27.11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$27.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$17.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,17.75,25.5,33.25,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.7,15.723076923076922,17.746153846153845,19.769230769230766,21.79230769230769,23.815384615384616,25.838461538461537,27.86153846153846,29.884615384615383,31.907692307692304,33.93076923076923,35.95384615384616,37.97692307692307,{"y":40,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.7,14.731538461538461,15.763076923076923,16.794615384615383,17.826153846153844,18.857692307692307,19.889230769230767,20.92076923076923,21.95230769230769,22.98384615384615,24.015384615384615,25.046923076923076,26.07846153846154,{"y":27.11,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.7,13.953846153846154,14.207692307692307,14.461538461538462,14.715384615384615,14.96923076923077,15.223076923076922,15.476923076923077,15.73076923076923,15.984615384615385,16.23846153846154,16.49230769230769,16.746153846153845,{"y":17,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":23.81,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":23.81,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.97,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.24,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.14,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.69,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.94,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.02,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.21,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.53,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.47,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.7,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >